Contribution: Industrial Research Assistance Program – Contributions to Firms
Diamond Therapeutics Inc.
$75,000.00
A feasibility study to determine the potential to develop a low dose solid dose formulation of psilocybin.
FY 2023-24 · 2023-04-01
Summary
The project aims to develop a solid dose formulation of Diamond Therapeutic's first drug candidate for use in advanced clinical studies. Requirments for formulation development for a later stage clinical program include certain stability and other characteristics necessary for a regulatory approval and ultimately a commercial product.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
739218683
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2023-04-01 | 2023-24 | $75,000.00 |
| 1 | 2023-04-01 | 2023-24 | $75,000.00 |
| 2 | 2023-04-01 | 2023-24 | $75,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 199 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 199 jours.
Agreement End Date
2024-09-30
Agreement Number
1005949
Agreement Start Date
2023-04-01
Agreement Title
A feasibility study to determine the potential to develop a low dose solid dose formulation of psilocybin.
Agreement Title (French)
Une étude de faisabilité pour déterminer le potentiel de développement d’une formulation de psilocybine à faible dose et à dose solide.
Agreement Type
Contribution
Agreement Value
$75,000.00
Amendment Date
2024-03-26
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The project aims to develop a solid dose formulation of Diamond Therapeutic's first drug candidate for use in advanced clinical studies. Requirments for formulation development for a later stage clinical program include certain stability and other characteristics necessary for a regulatory approval and ultimately a commercial product.
Description (French)
Le projet vise à développer une formulation à dose solide du premier médicament candidat de Diamond Therapeutic en vue de son utilisation dans des études cliniques avancées. Les exigences pour le développement d’une formulation pour un programme clinique à un stade plus avancé comprennent certaines caractéristiques de stabilité et d’autres caractéristiques nécessaires pour une approbation réglementaire et finalement un produit commercial.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
University--Rosedale
Federal Riding (French)
University--Rosedale
Federal Riding Number
35110
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
739218683
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
Diamond Therapeutics Inc.
Recipient Operating Name
Diamond
Recipient Postal Code
M5R 1T9
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2023-2024-Q2-1005949
